Spots Global Cancer Trial Database for neoplasms by site
Every month we try and update this database with for neoplasms by site cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Registry Study of Breast Microseed Treatment | NCT02701244 | Breast Neoplasm... | Permanent Breas... | 50 Years - | Concure Oncology-Breast Microseed Inc. | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Drainage After Rectal Excision for Rectal Cancer | NCT01269567 | Rectal Cancer S... Randomized Clin... Multicenter Stu... Pelvic Drainage | Laying and mana... No pelvic drain... | 18 Years - | University Hospital, Bordeaux | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy | NCT05022667 | Thyroid Neoplas... Thyroid Disease... Hypoparathyroid... Endocrine Syste... Endocrine Gland... Neoplasms by Si... Neoplasms Head and Neck N... Parathyroid Dis... | PTeye | 18 Years - | University of Michigan | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases | NCT05322486 | Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Neoplasms Neoplasms, Seco... Neoplasm Metast... Digestive Syste... Gastrointestina... Colonic Disease Intestinal Dise... Rectal Diseases | surgery of the ... chemotherapy | 18 Years - | State Scientific Centre of Coloproctology, Russian Federation | |
| Protection of Rectum From High Radiation Doses Using a Spacer | NCT01918605 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | Diluted spacer Non-diluted spa... | 50 Years - 78 Years | University of Oulu | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease | NCT01819766 | Inflammatory Bo... Primary Scleros... Colorectal Neop... Colorectal Canc... | 18 Years - 84 Years | Exact Sciences Corporation | ||
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies | NCT01260168 | Colorectal Neop... Digestive Syste... Colonic Disease... Colorectal Canc... | 40 Years - 90 Years | Exact Sciences Corporation | ||
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | NCT04679675 | Uterine Cervica... Uterine Neoplas... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Uterine Cervica... Uterine Disease... Cervical Cancer Cervical Dyspla... Human Papilloma... HPV-Related Cer... HPV Infection HPV-Related Mal... | Usual Care Education Direct Mail Opt-in | 30 Years - 64 Years | Kaiser Permanente | |
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
| Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer | NCT01397747 | Colorectal Neop... Digestive Syste... Colonic Disease... Colorectal Canc... | 50 Years - 84 Years | Exact Sciences Corporation | ||
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | NCT04461509 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Genital Disease... Prostatic Disea... | 18F-PSMA | 18 Years - | Cedars-Sinai Medical Center | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer | NCT01574222 | Non-Small Cell ... | autologous dend... | 21 Years - | VA Office of Research and Development | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | NCT01995942 | Adenocarcinoma Rectal Diseases Colorectal Neop... Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Studying Normal Breast Tissue and Cancer Risk | NCT00341692 | Breast Neoplasm... Neoplasms by Si... Neoplasms Breast Diseases Skin Diseases | 11 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | NCT04225299 | Localized Prost... | TOOKAD® | 18 Years - | Steba Biotech S.A. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | NCT03555422 | Endometrial Can... | Selinexor Matching placeb... | 18 Years - | Karyopharm Therapeutics Inc | |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | NCT03555422 | Endometrial Can... | Selinexor Matching placeb... | 18 Years - | Karyopharm Therapeutics Inc | |
| An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer | NCT01397305 | Rectal Cancer | [6R] 5,10-methy... Pemetrexed | 18 Years - | Isofol Medical AB | |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02766699 | Glioblastoma Astrocytoma, Gr... | EGFR(V)-EDV-Dox | 18 Years - | Engeneic Pty Limited | |
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | NCT02134015 | Lung Cancer Non-small Cell ... | Patritumab Erlotinib Placebo | 20 Years - | Daiichi Sankyo | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | NCT01966289 | Metastatic Colo... | CY GVAX SGI-110 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) | NCT02633800 | Head and Neck N... | Patritumab Cetuximab Cisplatin Carboplatin Placebo | 18 Years - | Daiichi Sankyo | |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815 | Metastatic Panc... | Gemcitabine, na... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | NCT02112656 | Hepatocellular ... | ThermoDox Dummy infusion | 18 Years - | Imunon | |
| SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | NCT01966289 | Metastatic Colo... | CY GVAX SGI-110 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer | NCT01472146 | Breast Cancer Breast Disease Neoplasms Neoplasms by Si... | Zo-Nantax | 18 Years - 75 Years | Instituto Nacional de Cancer, Brazil | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen | NCT05113134 | Colorectal Neop... Urologic Neopla... Gastrointestina... Neoplasms by Si... | Transvaginal na... | 20 Years - | Seoul National University Bundang Hospital | |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy | NCT05941897 | Advanced or Met... | Ceralasertib Durvalumab | 18 Years - | AstraZeneca | |
| Microbiome Test for the Detection of Colorectal Polyps and Cancer | NCT02141945 | Colorectal Neop... Colorectal Canc... | 45 Years - 80 Years | Metabiomics Corp | ||
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | NCT04597411 | Prostatic Neopl... | 225^Ac-PSMA-617 68^Ga-PSMA-11 | 18 Years - | Endocyte | |
| SMS-based Summons in Cervical Screening | NCT04061967 | Cervical Cancer Uterine Cervica... Uterine Neoplas... Genital Neoplas... Genital Neoplas... Uterine Disease... Genital Disease... Neoplasms by Si... Neoplasms Uterine Cervica... | Sending of scre... | 33 Years - 75 Years | Karolinska Institutet | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strategies | NCT03569605 | Physical Activi... Neoplasms Neoplasms by Si... Cancer | Self-help Intervention | 18 Years - 39 Years | UNC Lineberger Comprehensive Cancer Center | |
| A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | NCT02578797 | Castration-Resi... | Apalutamide | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
